ライフサイエンスコーパス: brain natriuretic peptide

1 phosphate) on binding of ANP, BNP (atrial or brain natriuretic peptide).

2 ality-of-life, and NT-proBNP (N-terminal pro-brain natriuretic peptide).

3 nction, and elevated baseline N-terminal pro-brain natriuretic peptide.

4 ponin I, creatine kinase, and N-terminal pro-brain natriuretic peptide.

5 sed plasma norepinephrine and n-terminal pro-brain natriuretic peptide.

6 tudinal strain, and N-terminal prohormone of brain natriuretic peptide.

7 adjustment for traditional risk factors and brain natriuretic peptide.

8 several biomarkers, including N-terminal pro-brain natriuretic peptide.

9 aseline levels of hs-cTnT and N-terminal pro-brain natriuretic peptide.

10 e prognostication in conjunction with plasma brain natriuretic peptide.

11 vated high-sensitivity C-reactive protein or brain natriuretic peptide.

12 kely to have elevated C-reactive protein and brain natriuretic peptide.

13 receptor for atrial natriuretic peptide and brain natriuretic peptide.

14 osin heavy chains, skeletal alpha-actin, and brain natriuretic peptide.

15 ch immunoassay protocol for the detection of brain natriuretic peptide.

16 l class, and higher levels of N-terminal pro-brain natriuretic peptide.

17 brain natriuretic peptide or N-terminal pro-brain natriuretic peptide.

18 e, invasive hemodynamics, and N-terminal pro-brain natriuretic peptide.

19 c structure and function, and N-terminal pro brain natriuretic peptide.

20 with lower circulating levels of atrial and brain natriuretic peptides.

21 class, medical therapy escalation, and BNP [brain natriuretic peptide]).

22 pmol/L, P=0.041), and had a trend to higher brain natriuretic peptide (12.3 versus 7.2 pmol/L, P=0.0

23 rathyroid hormone, prolactin, N-terminal pro-brain natriuretic peptide, 25-hydroxyvitamin D) and 2 no

24 3 +/- 0.006 mug/L, P = 0.003; N-terminal pro-brain natriuretic peptide, 38.1 +/- 37.7 vs. 5.9 +/- 12.

25 nt protein 1 (117 pg/mL; 119%; P=0.004), and brain natriuretic peptide (40 pg/mL; 57%; P=0.04).

26 tors of reduced survival were elevated serum brain natriuretic peptide (482 +/- 337 pg/mL) and uric a

27 Induction of both brain natriuretic peptide (5.8-fold versus control, P:<0

28 ansformed BNP and LV-GLS were 4.04 (absolute brain natriuretic peptide: 60 pg/dL) and -20.7%.

29 racoronary group, P=0.03) and N-terminal pro-brain natriuretic peptide (-628 +/- 211 versus -315 +/-

30 131 m; P = 0.001), and serum N-terminal pro-brain natriuretic peptide (647 +/- 1,127 pg/ml vs. 1,578

31 (mean, 66 years), gender (74% male), plasma brain natriuretic peptide (79 pg/mL), left ventricular e

32 iblings, had higher levels of N-terminal pro-brain natriuretic peptide (81.7 and 69.0 pg/mL, respecti

33 and the NT-proBNP (N-terminal prohormone of brain natriuretic peptide)-a biomarker that is used for

34 Cardiac hormones atrial and brain natriuretic peptides activate guanylyl cyclase/nat

35 l prognostic information to that provided by brain natriuretic peptide alone.

36 of patients misclassified by N-terminal pro-brain natriuretic peptide and 59% (95% confidence interv

37 Patients with high brain natriuretic peptide and aminoterminal propeptide o

38 PET coupled with biologic biomarkers such as brain natriuretic peptide and antineutrophilic cytoplasm

39 Brain natriuretic peptide and atrial natriuretic peptide

40 ained even in the presence of N-terminal pro-brain natriuretic peptide and high-sensitivity troponin

41 was robustly associated with N-terminal pro-brain natriuretic peptide and incident HF or death.

42 parallel with improvement in N-terminal pro-brain natriuretic peptide and left atrial size suggest t

43 =1) at 1 month is predictive, in addition to brain natriuretic peptide and LV ejection fraction, of d

44 fraction who underwent mitral valve surgery, brain natriuretic peptide and LV-GLS provided synergisti

45 tively with pulmonary hemodynamics and serum brain natriuretic peptide and negatively with 6-minute w

46 ly specific, PlGF, as well as N-terminal pro-brain natriuretic peptide and soluble vascular cell adhe

47 atrial size) with concomitant N-terminal pro-brain natriuretic peptide and subsequent HF hospitalizat

48 as significant-but-subclinical increases in brain natriuretic peptide and troponin I.

49 , echocardiography, assays of N-terminal pro-brain natriuretic peptide and Troponin T, and functional

50 Elevated brain natriuretic peptide and uric acid, decreased left

51 Significant falls occurred in plasma brain natriuretic peptide and urinary metadrenaline excr

52 -regulation of atrial natriuretic factor and brain natriuretic peptide and with increased expression

53 ctional capacity, biomarkers (N-terminal pro-brain natriuretic peptide and/or high-sensitivity tropon

54 nsumption), biomarker (N-terminal prohormone brain natriuretic peptide), and left ventricular functio

55 ongitudinal strain, N-terminal prohormone of brain natriuretic peptide, and adverse cardiac outcomes

56 These findings were all independent of brain natriuretic peptide, and assessment of NRG-1beta a

57 ded traditional risk factors, N-terminal pro-brain natriuretic peptide, and baseline hs-cTnT level.

58 hic marker genes, atrial natriuretic factor, brain natriuretic peptide, and beta-myosin heavy chain.

59 ), 6-minute walk distance, cardiac function, brain natriuretic peptide, and Borg dyspnea index.

60 llment, randomized treatment, N-terminal pro-brain natriuretic peptide, and clinical risk factors.

61 ment in ventricular function, N-terminal pro-brain natriuretic peptide, and exercise capacity compare

62 ge were measured (troponin T, N-terminal pro-brain natriuretic peptide, and heart-type fatty acid bin

63 es and ejection fraction with N-terminal pro-brain natriuretic peptide, and high-sensitive troponin w

64 rinogen, D-dimer, troponin T, N-terminal pro-brain natriuretic peptide, and high-sensitivity C-reacti

65 tus, cardiac status including measurement of brain natriuretic peptide, and leukocyte antibody testin

66 Embolism Severity Index, cardiac troponin I, brain natriuretic peptide, and lower limb ultrasound tes

67 ease, chronic kidney disease, N-terminal-pro brain natriuretic peptide, and lymphocyte GRK2 protein l

68 , previous cardiopulmonary disease, D-dimer, brain natriuretic peptide, and percentage of pulmonary v

69 aphy, echocardiography, serum N-terminal pro-brain natriuretic peptide, and pulmonary function tests

70 ler-derived E/e' at echocardiography, plasma brain natriuretic peptide, and quality-of-life scores.

71 eased expression of beta-myosin heavy chain, brain natriuretic peptide, and skeletal actin and a decr

72 functional class, serum levels of N-terminal brain natriuretic peptide, and time to clinical worsenin

73 concentrations of vasopressin, aldosterone, brain natriuretic peptide, and total renin were measured

74 Although neither atrial nor brain natriuretic peptide (ANP, BNP) is amidated, the ma

75 Atrial and brain natriuretic peptides (ANP and BNP, respectively) a

76 of beta-myosin heavy chain (betaMHC), atrial/brain natriuretic peptides (ANP/BNP), and skeletal alpha

77 gh-sensitivity troponin I and N-terminal pro-brain natriuretic peptide are also prognostic in patient

78 Atrial and brain natriuretic peptides are cleaved into smaller biol

79 First, data on the use of brain natriuretic peptide as a screening biomarker has s

80 The use of brain natriuretic peptide as a screening tool for asympt

81 , 6-minute walk distance, and N-terminal pro-brain natriuretic peptide as secondary endpoints.

82 Brain natriuretic peptide as well as biomarkers of myoca

83 onsistent effect on N-terminal prohormone of brain natriuretic peptide at 18 months was observed in t

84 Patisiran lowered N-terminal prohormone of brain natriuretic peptide at 9 and 18 months (at 18 mont

85 ) damage and of decongestion (N-terminal pro-brain natriuretic peptide) at day 2 and worsening heart

86 ptide levels, and cardiac mRNA expression of brain natriuretic peptide, atrial natriuretic factor, an

87 Multivariable regression revealed that brain natriuretic peptide (beta=-0.250; P<0.001) and rec

88 phy gene markers atrial natriuretic peptide, brain natriuretic peptide, beta-myosin heavy chain and m

89 N-terminal pro-brain natriuretic peptide blood levels decreased by 620

90 ort-term administration of subcutaneous (SQ) brain natriuretic peptide (BNP) administration during th

91 We sampled brain natriuretic peptide (BNP) and amino-terminal (NT)-

92 Baseline brain natriuretic peptide (BNP) and C-reactive protein (

93 sed less atrial natriuretic factor (ANF) and brain natriuretic peptide (BNP) and more glucose transpo

94 Brain natriuretic peptide (BNP) and N-terminal pro-brain

95 Brain natriuretic peptide (BNP) and N-terminal proBNP (N

96 We examined whether changes in brain natriuretic peptide (BNP) and norepinephrine (NE)

97 Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) are sensitive biomarkers

98 orts have suggested the usefulness of plasma brain natriuretic peptide (BNP) as a screening test for

99 mited data on the prognostic implications of brain natriuretic peptide (BNP) assessment in patients w

100 actor of activated T cells -c3 (NFATc3), and brain natriuretic peptide (BNP) compared to controls.

101 re, assessed by history of heart failure and brain natriuretic peptide (BNP) concentration at baselin

102 mine the effects of age and gender on plasma brain natriuretic peptide (BNP) concentration in a popul

103 Brain natriuretic peptide (BNP) gene expression is a wel

104 xpression profile analysis revealed that the brain natriuretic peptide (BNP) gene was significantly u

105 Brain natriuretic peptide (BNP) has an established role

106 The renal actions of brain natriuretic peptide (BNP) in congestive heart fail

107 chronic subcutaneous (SQ) administration of brain natriuretic peptide (BNP) in experimental CHF impr

108 Brain natriuretic peptide (BNP) is a cardiac peptide wit

109 Brain natriuretic peptide (BNP) is a marker of diagnosis

110 It is unknown if brain natriuretic peptide (BNP) is synthesized by CFs an

111 tional class (HR 1.50; 95% CI 1.02-2.2), log brain natriuretic peptide (BNP) levels (HR 1.45; 95% CI

112 Brain natriuretic peptide (BNP) levels are used in the e

113 ctive study to evaluate whether preoperative brain natriuretic peptide (BNP) levels predict postopera

114 o cardiac volume loading and increased serum brain natriuretic peptide (BNP) levels.

115 We sought to determine the usefulness of brain natriuretic peptide (BNP) measurements to differen

116 We postulated that plasma brain natriuretic peptide (BNP) might serve as a biomark

117 not innervated by pruritoceptors expressing brain natriuretic peptide (BNP) most of them contained m

118 vs. 443 ms; P = 0.05), an elevated pre-TIPS brain natriuretic peptide (BNP) or N-terminal pro-brain

119 a, congestion on chest radiograph, increased brain natriuretic peptide (BNP) or N-terminal prohormone

120 ongestion on chest radiograph, and increased brain natriuretic peptide (BNP) or N-terminal prohormone

121 Brain natriuretic peptide (BNP) serum concentration has

122 sought to derive a new staging system using brain natriuretic peptide (BNP) that would correlate wit

123 time of admission the plasma level of plasma brain natriuretic peptide (BNP) to determine its utility

124 Brain natriuretic peptide (BNP) treatment increases hear

125 crosis factor-alpha receptor-1 (sTNFR-1) and brain natriuretic peptide (BNP) were highly predictive o

126 cid for atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) were increased 7- and 3-

127 the sodium calcium exchanger (Ncx1) and the brain natriuretic peptide (Bnp) whose hypertrophic upreg

128 nstant of the interaction of a 32-amino acid brain natriuretic peptide (BNP) with a mAbs and demonstr

129 agenesis to characterize the interactions of brain natriuretic peptide (BNP) with two monoclonal anti

130 tified angiotensin II as a potent inducer of brain natriuretic peptide (BNP), a hormone that recently

131 diac hormones atrial natriuretic peptide and brain natriuretic peptide (BNP), but little is known abo

132 rations of atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), endothelin-1 (ET-1), re

133 rial natriuretic peptide (ANP) and B-type or brain natriuretic peptide (BNP), in the general communit

134 cluding atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), is a hallmark for malad

135 r levels of atrial natriuretic factor (ANF), brain natriuretic peptide (BNP), the RNA helicase Csm, a

136 xpression for the natriuretic peptides [ANP, brain natriuretic peptide (BNP), type-C natriuretic pept

137 te (cGMP), nitrosative/oxidative stress, and brain natriuretic peptide (BNP).

138 nction, exercise capacity, heart rhythm, and brain natriuretic peptide (BNP).

139 ctivity (44+/-15%, P<0.05) in processing pro-brain natriuretic peptide (BNP).

140 h atrial natriuretic peptide (ANP), and with brain natriuretic peptide (BNP).

141 transcription factor activates expression of brain natriuretic peptide (BNP).

142 al proatrial natriuretic peptide (N-ANP) and brain natriuretic peptide (BNP).

143 Monoclonal antibody (mAb) 106.3 binds brain natriuretic peptide (BNP)5-13(C10A) and full-lengt

144 omodulin (sTM)]) and raised plasma levels of brain natriuretic peptide (BNP, a peptide hormone associ

145 40% or less, elevated natriuretic peptides (brain natriuretic peptide [BNP] >/= 400 pg/mL or N -term

146 the fiber direction increased expression of brain natriuretic peptide, but off-axis stretches (causi

147 Brain natriuretic peptide can be useful in distinguishin

148 and blood samples were evaluated for cardiac brain natriuretic peptide, choline, and TMAO levels.

149 Independent predictors were brain natriuretic peptide concentration > or =300 pg/ml

150 Brain natriuretic peptide concentration ranged from <4 t

151 Of those without LVSD, plasma N-terminal pro-brain natriuretic peptide concentration was greater than

152 t-for-age z score, Ross heart failure class, brain natriuretic peptide concentration, Bayley scores o

153 r volume, including central venous pressure, brain-natriuretic-peptide concentration, and fractional

154 alked in 6 min, and N-terminal prohormone of brain natriuretic peptide concentrations between the 2 g

155 lecules, and plasma N-terminal prohormone of brain natriuretic peptide concentrations were also measu

156 ss, Minnesota quality-of-life questionnaire, brain natriuretic peptide concentrations, and 6-minute w

157 and baseline and increases in N-terminal pro-brain natriuretic peptide concentrations.

158 anti-mitogenic activities of the atrial and brain natriuretic peptides depend upon their binding to

159 or persistently elevated amino terminal pro-brain natriuretic peptide despite treatment for heart fa

160 ome clinical information (eg, N terminal pro-brain natriuretic peptide, distinctive chest x-ray findi

161 ependent after adjustment for N-terminal pro-brain natriuretic peptide, ejection fraction, stroke vol

162 Perfusion of isolated guinea pig hearts with brain natriuretic peptide elicited a 3-fold increase in

163 tivity cardiac troponin T and N-terminal pro-brain natriuretic peptide) emerged as the most powerful

164 vity, right ventricular function, as well as brain natriuretic peptide, endothelin-1, uric acid, and

165 Only 4 drugs (brain natriuretic peptide, exenatide, metoprolol, and es

166 dent protein kinase IIdelta phosphorylation, brain natriuretic peptide expression, and sustained capi

167 r activity and suppressed ET-induced ANP and brain natriuretic peptide gene expression.

168 6 [1.02-3.39]; P=0.043) 1 month after MI and brain natriuretic peptide >100 pg/mL (2.35 [1.28-4.31];

169 N-terminal prohormone of brain natriuretic peptide >8500 ng/L could not be overco

170 re and for improved clinical outcomes with a brain natriuretic peptide-guided approach to heart failu

171 Additionally, brain natriuretic peptide has garnered significant inter

172 ntricular ejection fraction, creatinine, and brain natriuretic peptide (hazard ratio, 0.58 [95% CI, 0

173 2.133; p = 0.040), as well as N-terminal pro-brain natriuretic peptide (hazard ratio: 1.655; p < 0.00

174 ogical activity of orally administered human brain natriuretic peptide (hBNP).

175 ogate markers were evaluated: N-terminal-pro brain natriuretic peptide, high-sensitivity C-reactive p

176 Inclusion of N-terminal pro-brain natriuretic peptide improved the overall classific

177 However, studies of brain natriuretic peptide in patients with heart failure

178 Strong evidence exists for use of brain natriuretic peptide in the diagnosis of acute hear

179 In HF-CON, n-terminal pro-brain natriuretic peptide increased by 88 +/- 120 pg/mL

180 Importantly, proBNP (pro-brain natriuretic peptide) increased at 12 months in 20

181 nt and dysfunction and higher N-terminal pro brain natriuretic peptide independent of RA size and pre

182 Brain natriuretic peptide is the most widely studied, wi

183 Nesiritide (synthetic human brain natriuretic peptide) is approved for the treatment

184 tic peptide, and assessment of NRG-1beta and brain natriuretic peptide jointly provided better risk s

185 on problem list, inpatient loop diuretic, or brain natriuretic peptide level of 500 pg/mL or higher;

186 ; mean EF was 56%; and median N-terminal pro-brain natriuretic peptide level was 1403 pg/mL; 761 (96.

187 f patients were women, median N-terminal pro-brain natriuretic peptide level was 918 pg/ml (interquar

188 logy and to the subgroup with baseline serum brain natriuretic peptide levels >/=100 pg/mL.

189 [CI], -2, -16; n = 13, p = 0.015) and plasma brain natriuretic peptide levels (-19.4 fmol x ml(-1); 9

190 Secondary endpoints included brain natriuretic peptide levels and catecholamine excre

191 ment was also associated with a reduction of brain natriuretic peptide levels and no increase in the

192 igh-sensitivity troponin, and N-terminal pro-brain natriuretic peptide levels are predictive of death

193 Brain natriuretic peptide levels correlated moderately w

194 N-terminal prohormone brain natriuretic peptide levels did not increase signif

195 eased lung/body weight ratios, and increased brain natriuretic peptide levels in cMyBP-C(t3SA) mice d

196 Brain natriuretic peptide levels on admission were lower

197 At follow-up, brain natriuretic peptide levels remained stable in grou

198 r reductions from baseline in N-terminal pro-brain natriuretic peptide levels than did the pooled-mon

199 nd control groups; only serum creatinine and brain natriuretic peptide levels varied in laboratory ev

200 ysaccharide binding protein, troponin T, and brain natriuretic peptide levels were measured.

201 put, decreased wedge pressure, and decreased brain natriuretic peptide levels were observed in animal

202 New diagnostic tests (troponin and brain natriuretic peptide levels) are being used to aid

203 Plasma brain natriuretic peptide levels, and cardiac mRNA expre

204 um oxygen consumption, N-terminal prohormone brain natriuretic peptide levels, and left ventricular e

205 tion, plasma norepinephrine, angiotensin II, brain natriuretic peptide levels, and medications.

206 rioperative changes in left atrial pressure, brain natriuretic peptide levels, lactic acid, or renal

207 , quality of life, incidence of arrhythmias, brain natriuretic peptide levels, left ventricular eject

208 is characterized by increased N-terminal pro-brain natriuretic peptide levels, troponin release, elev

209 ricular ejection fraction, or N-terminal pro-brain natriuretic peptide levels.

210 truction, such as exercise testing and serum brain natriuretic peptide levels.

211 as assessed by measurement of N-terminal pro-brain natriuretic peptide levels; the rate of recurrent

212 NT-proBNP (N-terminal pro brain natriuretic peptide) levels are included in the mu

213 of diabetes mellitus, higher N-terminal pro-brain natriuretic peptide, lower estimated glomerular fi

214 homocysteine <10 micromol/L, N-terminal pro-brain natriuretic peptide <100 pg/mL, no microalbuminuri

215 The inclusion of N-terminal pro-brain natriuretic peptide markedly improves HF risk pred

216 y echocardiography and plasma N-terminal pro-brain natriuretic peptide measurement and were followed

217 iopulmonary exercise testing, N-terminal pro-brain natriuretic peptide measurement, cardiac magnetic

218 alizations) hospitalizations in which either brain natriuretic peptide measures or ejection fraction

219 to compare urinary and plasma N-terminal pro-brain natriuretic peptide (N-BNP) in left ventricular sy

220 on) in comparison with plasma N-terminal pro-brain natriuretic peptide (N-BNP) levels.

221 erived cardiomyocytes and CFs via the atrial/brain natriuretic peptide-natriuretic peptide receptor-1

222 inical heart failure trials with recombinant brain natriuretic peptide (nesiritide) failed to prove i

223 diography, an increased serum N-terminal pro-brain natriuretic peptide (NT-pro-BNP) level, and pulmon

224 he predictive capabilities of N-terminal pro-brain natriuretic peptide (NT-proBNP) and C-reactive pro

225 Current staging systems use N-terminal pro-brain natriuretic peptide (NT-proBNP) and cardiac tropon

226 N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivi

227 ded whether the N-terminal of the prohormone brain natriuretic peptide (NT-proBNP) and high-sensitivi

228 The Hokusai-VTE study used N-terminal pro-brain natriuretic peptide (NT-proBNP) and right to left

229 ating plasma levels of N-terminal prohormone brain natriuretic peptide (NT-proBNP) and soluble vascul

230 Combining abnormal N-terminal pro-brain natriuretic peptide (NT-proBNP) and troponin T wit

231 Elevated levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are associated wit

232 troponins (cTnT and cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are prognostic in

233 natriuretic peptide (BNP) and N-terminal pro-brain natriuretic peptide (NT-proBNP) are well-establish

234 distance (6MWD) and change in N-terminal pro-brain natriuretic peptide (NT-proBNP) by after therapy.

235 dary efficacy measure was the N-terminal pro-brain natriuretic peptide (NT-proBNP) concentration afte

236 ized as biosensors to measure N-terminal pro-brain natriuretic peptide (NT-proBNP) in human serum wit

237 The ventricular N-terminal pro-brain natriuretic peptide (NT-proBNP) is a marker of CHF

238 Others have reported that N-terminal pro-brain natriuretic peptide (NT-proBNP) is a valuable prog

239 natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-proBNP) level, an elevated

240 ulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) level, World Healt

241 n renal insufficiency and amino-terminal pro-brain natriuretic peptide (NT-proBNP) levels remains unc

242 ery in patients with elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, reduces th

243 ulmonary vascular resistance, N-terminal pro-brain natriuretic peptide (NT-proBNP) levels, World Heal

244 etween renal function and amino-terminal pro-brain natriuretic peptide (NT-proBNP) levels.

245 but is associated with lower N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.

246 ured troponin T and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) on postoperative d

247 Levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) provide such infor

248 The biomarker N-terminal pro-brain natriuretic peptide (NT-proBNP) was assessed.

249 N-terminal brain natriuretic peptide (NT-proBNP) was significantly

250 /ml; p < 0.001), although amino-terminal pro-brain natriuretic peptide (NT-proBNP) was superior to ST

251 biomarkers (such as N-terminal prohormone of brain natriuretic peptide (NT-proBNP)) and a measure of

252 vestigated whether plasma amino-terminal pro-brain natriuretic peptide (NT-proBNP), a marker of cardi

253 sitivity troponin T (hs-TnT), N-terminal pro-brain natriuretic peptide (NT-proBNP), and growth differ

254 cardiac troponin T (cTnT) and N-terminal pro-brain natriuretic peptide (NT-proBNP).

255 walk distance, and levels of N-terminal pro-brain natriuretic peptide (NT-proBNP).

256 O functional class, N-terminal prohormone of brain natriuretic peptide (NT-proBNP)concentrations, Bor

257 s 0.37 +/- 0.04, P = .01) and N-terminal pro-brain natriuretic peptide (NT-proBNP; 191 +/- 261 vs 33

258 T; cardiac injury biomarker), N-terminal pro-brain natriuretic peptide (NT-proBNP; cardiomyopathy bio

259 ng distance [6MWD], N-terminal prohormone of brain natriuretic peptide [NT-proBNP] concentration, and

260 ] symptom classification, and N-terminal pro-brain natriuretic peptide [NT-proBNP] level) at 6 months

261 (troponins I and T, N-terminal prohormone of brain natriuretic peptide [NT-proBNP]) to predict baseli

262 C-reactive protein [hs-CRP], N-terminal pro-brain natriuretic peptide [NT-proBNP], white blood cell

263 IIIB (that is stage III with N-terminal pro-brain natriuretic peptide [NTproBNP] >8500 pg/mL) diseas

264 action of nitric oxide-CAPON signalling and brain natriuretic peptide on cGMP and cAMP regulation of

265 action, and an elevated circulating level of brain natriuretic peptide or N-terminal pro-brain natriu

266 body mass index (p = 0.002), N-terminal pro-brain natriuretic peptide (p < 0.001), early mitral infl

267 P = .703), TRV (P = .503), or N-terminal pro-brain natriuretic peptide (P = .410).

268 04), and had higher levels of N-terminal pro-brain natriuretic peptide (p = 0.001) compared with less

269 erobic exercise capacity, and N-terminal pro-brain natriuretic peptide (P>0.30 for all).

270 tly correlated with N-terminal prohormone of brain natriuretic peptide (P<0.001), 6-minute walk dista

271 (IL)-6 (P=0.019), and N-terminal prohormone brain natriuretic peptide (P=0.028) concentrations were

272 nal pediatric definition; P=0.087) and lower brain natriuretic peptide (P=0.060).

273 [P = .03]), and markers of cardiac stretch (brain natriuretic peptide [P < .001] and N-terminal frag

274 1] and N-terminal fragment of the prohormone brain natriuretic peptide [P = .001]) in HIV.

275 sure and heart rate, 6-minute walk distance, brain natriuretic peptide, percent predicted carbon mono

276 patient's age, race, sex, and N-terminal pro-brain natriuretic peptide performs comparably to the ful

277 tumor necrosis factor-alpha receptor II, pro-brain natriuretic peptide (pro-BNP), and cardiac troponi

278 e LV global longitudinal strain (LV-GLS) and brain natriuretic peptide provided incremental prognosti

279 significant correlations with N-terminal pro-brain natriuretic peptide (R=0.69, P<0.001) and Troponin

280 clinically used biomarkers of heart failure: brain natriuretic peptide (r=0.691; P=0.0003), QRS (r=0.

281 oponin T (cTnT) and N-terminal prohormone of brain natriuretic peptide) related to hemodynamic activi

282 hematologic response and the N-terminal pro-brain natriuretic peptide response.

283 rography (MRN) with hsTNT and N-terminal pro-brain natriuretic peptide serum levels in patients with

284 a ratios, fetal gene expressions (atrial and brain natriuretic peptides, skeletal actin, beta-myosin

285 lified Pulmonary Embolism Severity Index and brain natriuretic peptide testing showed a negative pred

286 ood pressure and in levels of N-terminal pro-brain natriuretic peptide than the placebo group.

287 as well as a higher level of N-terminal pro-brain natriuretic peptide, than noncarriers (1194 partic

288 On addition of N-terminal pro-brain natriuretic peptide, the optimism-corrected area u

289 miR-150 outperformed N-terminal pro-brain natriuretic peptide to predict remodeling (area un

290 left atrial volume, N-terminal propeptide of brain natriuretic peptide, total, collagen-dependent, an

291 LV ejection fraction, plasma n-terminal pro-brain natriuretic peptide, tumor necrosis factor-alpha,

292 , plasma concentration of amino terminal pro-brain natriuretic peptide (univariate and multivariable

293 n, LV volumes, scar size, and N-terminal pro-brain natriuretic peptide values comparing the 2 treatme

294 eft ventricular ejection fraction, and lower brain natriuretic peptide values on admission.

295 er adjusting for serum interleukin-6 levels, brain natriuretic peptide values, and glucocorticoid use

296 25% (SD, 8) and median plasma N-terminal pro-brain natriuretic peptide was 3,070 pg/ml (interquartile

297 y decrease and no decrease in N-terminal-pro-brain natriuretic peptide was not reached and 26 months,

298 Median levels of brain natriuretic peptide were 550 pg/mL in patients wit

299 iotensin II, atrial natriuretic peptide, and brain natriuretic peptide were measured at baseline.

300 n, plasma norepinephrine, and n-terminal pro-brain natriuretic peptide were measured before (pre) and